Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Grows By 55.1%

Context Therapeutics Inc. (NASDAQ:CNTX) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 1,530,000 shares, a growth of 55.1% from the December 15th total of 986,300 shares. Based on an average trading volume of 501,500 shares, the days-to-cover ratio is presently 3.1 days. Currently, 2.6% of the company’s stock are sold short.

Analyst Ratings Changes

Several research firms have recently weighed in on CNTX. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Wednesday. JMP Securities assumed coverage on Context Therapeutics in a research note on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a research report on Monday, September 23rd. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $6.33.

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Clear Harbor Asset Management LLC increased its holdings in shares of Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after acquiring an additional 21,804 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Context Therapeutics in the 3rd quarter worth about $89,000. Renaissance Technologies LLC increased its stake in shares of Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after purchasing an additional 25,300 shares during the period. State Street Corp raised its holdings in shares of Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after buying an additional 19,800 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its position in shares of Context Therapeutics by 392.4% during the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after buying an additional 1,290,323 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Trading Up 3.2 %

NASDAQ CNTX traded up $0.03 during trading hours on Friday, reaching $1.01. The company’s stock had a trading volume of 259,944 shares, compared to its average volume of 366,240. The business has a 50-day simple moving average of $1.36 and a 200 day simple moving average of $1.89. Context Therapeutics has a 52 week low of $0.89 and a 52 week high of $2.75. The stock has a market cap of $75.75 million, a PE ratio of -1.11 and a beta of 2.10.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11). As a group, equities analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.